Latham & Watkins represented the underwriters in the IPO while Goodwin advised PepGen. PepGen, Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here